Physician profile
Jonathan S Matthew
NPI 1124085881
$5,775.05
in general payments reported to CMS, 2019-2025
28 companies · $875 in 2025
The $875 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,772 · 2020: $828 · 2022: $83.49 · 2023: $813 · 2024: $1,403 · 2025: $875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,092.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,091.86 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,319.24 | 2019-2025 | |
| Janssen Biotech, INC. | $727.96 | 2019-2025 | Stelara, Tremfya |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $633.26 | 2019-2025 | Xifaxan, Trulance |
| Pfizer INC. | $505.66 | 2019-2025 | |
| Allergan, INC. | $389.92 | 2019 | |
| Ironwood Pharmaceuticals, INC | $309.32 | 2019-2025 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $279.63 | 2019-2020 | |
| Genzyme Corporation | $224.15 | 2022-2025 | |
| Janssen Scientific Affairs, LLC | $210.07 | 2019-2020 | |
| Ardelyx, INC. | $194.39 | 2024-2025 | Ibsrela |
| Celgene Corporation | $145.50 | 2023-2024 | Zeposia |
| Regeneron Healthcare Solutions, INC. | $126.05 | 2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $122.11 | 2024 | Zeposia |
| Phathom Pharmaceuticals, INC. | $105.87 | 2024-2025 | Voquezna |
| Intercept Pharmaceuticals, INC. | $61.29 | 2019-2020 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evoke Pharma, INC. | $44.96 | 2023 | Gimoti |
| Concordia Pharmaceuticals INC. | $44.66 | 2019 | |
| Ferring Pharmaceuticals INC. | $42.83 | 2019 | |
| Merck Sharp & Dohme LLC | $38.27 | 2019-2024 | Dificid |
| Capsovision, INC. | $36.09 | 2025 | Capsocam Plus |
| Gilead Sciences, INC. | $34.75 | 2019-2020 | |
| Madrigal Pharmaceuticals | $34.36 | 2025 | Rezdiffra |
| Braintree Laboratories, INC. | $31.16 | 2020 | |
| Qol Medical, LLC | $30.79 | 2019 | |
| Novo Nordisk INC | $28.71 | 2025 | Wegovy |
| Ucb, INC. | $25.34 | 2019 | |
| Smith+Nephew, INC. | $14.71 | 2022 | |
| Alfasigma USA, INC. | $14.00 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Matthew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.